Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
13,583
Total Claims
$876K
Drug Cost
842
Beneficiaries
$1,041
Cost/Patient
Risk Score Breakdown 32/100
Score components are additive. Read full methodology
Peer Comparison vs. 218,535 Nurse Practitioner providers
+661%
Opioid rate vs peers
28.8% vs 3.8% avg
-11%
Cost per patient vs peers
$1,041 vs $1,174 avg
-57%
Brand preference vs peers
3.8% vs 8.9% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Opioid prescribing rate is 661% above the average for Nurse Practitioner providers. While some providers legitimately treat pain-heavy populations, deviations of this magnitude are rare and warrant examination.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
28.8%
Opioid Rate
3,911
Opioid Claims
$111K
Opioid Cost
—
Long-Acting Rate
This provider's opioid prescribing rate of 28.8% is above the 20% threshold that CMS considers elevated.
Brand vs Generic
Brand: 517 claims · $580K
Generic: 13,046 claims · $295K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Pimavanserin Tartrate | 31 | $152K |
| Rimegepant Sulfate | 43 | $65K |
| Oxycodone Hcl/Acetaminophen | 1,840 | $57K |
| Eslicarbazepine Acetate | 30 | $45K |
| Hydrocodone/Acetaminophen | 1,646 | $45K |
| Cenobamate | 28 | $34K |
| Semaglutide | 26 | $28K |
| Galcanezumab-Gnlm | 33 | $24K |
| Vortioxetine Hydrobromide | 39 | $23K |
| Tirzepatide | 18 | $21K |
| Linaclotide | 30 | $18K |
| Erenumab-Aooe | 21 | $17K |
| Brivaracetam | 16 | $16K |
| Gabapentin | 1,110 | $14K |
| Naloxegol Oxalate | 23 | $13K |
Prescribing Profile
Patient Profile
65
Avg Age
63%
Female
1.53
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About